Login to Your Account

Novabay sinks on NVC-422 phase II torpedo in viral conjunctivitis

By Marie Powers
Staff Writer

Thursday, August 21, 2014
Shares of Novabay Pharmaceuticals Inc. (NYSE MKT:NBY) plunged 44 percent, to a one-year low of 69 cents, Wednesday morning after the company reported that its NVC-422 (auriclosene) ophthalmic formulation failed to meet the primary and secondary endpoints in a phase II study in patients with adenoviral conjunctivitis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription